Nolibeta (Nebivolol)

Nebivolol, the active ingredient in Nolibeta, is a beta blocker presented as a tablet for oral use. It treats hypertension and heart failure in adult patients.

GNH USA supplies Nolibeta as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol is used to manage cardiovascular conditions that involve elevated blood pressure or impaired cardiac function.

- Hypertension: lowers systemic blood pressure and reduces cardiovascular risk. - Chronic heart failure: improves left‑ventricular ejection fraction and decreases hospitalization rates. - Post‑myocardial infarction (when indicated): helps prevent subsequent cardiac events.

Nebivolol may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness or light‑headedness: especially on standing. - Fatigue: general tiredness. - Nasal congestion: mild blockage of nasal passages. - Bradycardia: slower than normal heart rate. - Gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects: - Severe bradycardia: heart rate dropping below 40 bpm. - Heart block: atrioventricular conduction disturbances. - Acute heart failure exacerbation. - Angioedema: swelling of face, lips, or throat. - Hypotension: marked drop in blood pressure causing faintness. - Liver enzyme elevation: abnormal hepatic function tests.

Before prescribing Nolibeta, clinicians should consider several safety aspects.

- Cardiovascular assessment: evaluate for severe bradycardia or heart block. - Renal function: adjust use in patients with significant renal impairment. - Hepatic impairment: use cautiously in moderate to severe liver disease. - Concomitant beta‑blockers: avoid additive effects that may cause excessive slowing of heart rate. - Pregnancy and lactation: assess risk‑benefit, as safety data are limited. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and light.

Nebivolol can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., paroxetine, quinidine): may increase nebivolol plasma levels. - Non‑dihydropyridine calcium channel blockers (e.g., verapamil, diltiazem): can cause excessive bradycardia. - Other beta‑blockers: additive negative chronotropic effects.

Moderate Interactions (Monitor Closely): - Antihypertensive agents (e.g., ACE inhibitors, diuretics): may enhance blood pressure lowering. - Antidiabetic drugs: nebivolol may mask hypoglycaemia symptoms. - NSAIDs: may reduce antihypertensive efficacy.